Size: | Price | Quantity | |
---|---|---|---|
5 mg | $45.00 | ||
25 mg | $150.00 |
Epacadostat (1204669-58-8) is a potent (IC50 = 10nM)1 and selective inhibitor of Indoleamine-2,3-dioxygenase 1 (IDO1) with no activity at IDO2 or TDO.2 It restored tryptophan levels and significantly impaired kynurenine generation in CT26 colon carcinoma (IC50 = 76 nM) and PAN02 pancreatic carcinoma (IC50 = 27 nM) cells. Epacadostat increases the number and activity of tumor-infiltrating lymphocytes as well as increasing the ratio of effector T cells to regulatory T cells.1,2 Because of these immune system enhancing properties3, it is being investigated as a synergistic agent for use with other immuno-oncology agents such as anti-PD-1 and anti-CTL4 antibodies.4-6
References/Citations:
1) Liu et al. (2010), Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity; Blood 115 3520
2) Koblish et al. (2010), Hydroxyamidine Inhibitors of Indolamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors; Mol. Cancer Ther. 9 489
3) Jochems et al. (2016), The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells; Oncotarget 7 37762
4) Yentz and Smith (2018), Indoleamine-2,3-dioxygenase Inhibition as a Strategy to Augment Cancer Immunotherapy; BioDrugs 32 311
5) Zhu et al. (2019), Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development; Curr. Oncol. Rep. 21 2
6) Mitchell et al. (2018), Epacadostat Plus Pembrolizumab in Patients with Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037); J. Clin. Oncol. 36 3223
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Epacadostat (1204669-58-8) is a potent (IC50 = 10nM)1 and selective inhibitor of Indoleamine-2,3-dioxygenase 1 (IDO1) with no activity at IDO2 or TDO.2 It restored tryptophan levels and significantly impaired kynurenine generation in CT26 colon carcinoma (IC50 = 76 nM) and PAN02 pancreatic carcinoma (IC50 = 27 nM) cells. Epacadostat increases the number and activity of tumor-infiltrating lymphocytes as well as increasing the ratio of effector T cells to regulatory T cells.1,2 Because of these immune system enhancing properties3, it is being investigated as a synergistic agent for use with other immuno-oncology agents such as anti-PD-1 and anti-CTL4 antibodies.4-6
References/Citations:
1) Liu et al. (2010), Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity; Blood 115 3520
2) Koblish et al. (2010), Hydroxyamidine Inhibitors of Indolamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors; Mol. Cancer Ther. 9 489
3) Jochems et al. (2016), The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells; Oncotarget 7 37762
4) Yentz and Smith (2018), Indoleamine-2,3-dioxygenase Inhibition as a Strategy to Augment Cancer Immunotherapy; BioDrugs 32 311
5) Zhu et al. (2019), Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development; Curr. Oncol. Rep. 21 2
6) Mitchell et al. (2018), Epacadostat Plus Pembrolizumab in Patients with Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037); J. Clin. Oncol. 36 3223
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.